{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-094758","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.878526+00:00","generated_at":"2026-05-17T05:14:56.771838+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials","bullets":["Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.","Net proceeds plus existing cash expected to fund operations into 2028, excluding full AXPAXLI commercial launch costs.","Funds to support AXPAXLI open-label extension in wet AMD, Phase 3 trials in NPDR, and manufacturing scale-up.","Offering expected to close Oct 1, 2025; BofA Securities, TD Cowen, Piper Sandler & Co. acting as joint book-runners."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-094758","json":"https://secwatch.observer/filing/0001104659-25-094758.json","markdown":"https://secwatch.observer/filing/0001104659-25-094758.md","text":"https://secwatch.observer/filing/0001104659-25-094758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/0001104659-25-094758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/tm2527344d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:14:56.771838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}